<table>
<thead>
<tr>
<th>HIGHLIGHTS</th>
<th>LARGE MOLECULE THERAPEUTICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>REVIEW</td>
<td>1283 Durvalumab Combined with Immunomodulatory Drugs (IMID) Overcomes Suppression of Antitumor Responses due to IMID-induced PD-L1 Upregulation on Myeloma Cells Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, and Hideto Tamura</td>
</tr>
<tr>
<td>1223 In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, and Roddy S. O’Connor</td>
<td>1295 Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy Bin Yi, Hao Cheng, Dorota Wyczecowska, Qingzhao Yu, Li Li, Augusto C. Ochoa, Adam I. Riker, and Yaguang Xi</td>
</tr>
<tr>
<td>SMALL MOLECULE THERAPEUTICS</td>
<td></td>
</tr>
<tr>
<td>1234 Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis Anu Gupta, Jarnail Singh, Alfonso Garcia-Valverde, César Serrano, Daniel L. Flynn, and Bryan D. Smith</td>
<td></td>
</tr>
<tr>
<td>1246 Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma Brent A. Willobee, Alexander A. Gaidarski, Austin R. Dosch, Jason A. Castellanos, Xizi Dai, Siddharth Mehra, Fanuel Messaggio, Supriya Srinivasan, Michael N. VanSaun, Nagaraj S. Nagathihalli, and Nipun B. Merchant</td>
<td></td>
</tr>
</tbody>
</table>
### TABLE OF CONTENTS

#### TARGETING DRUG RESISTANCE

**1305** Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas  
Hui Zhang, Yongyan Bi, Yuxi Wei, Jiayang Liu, Kudelaidi Kuerban, and Li Ye

#### COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

**1316** BRAFV600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis  
Chan-Juan Wang, Lei Cui, Hong-Hao Ma, Dong Wang, Li Zhang, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Tian-You Wang, Zhi-Gang Li, and Rui Zhang

---

**ABOUT THE COVER**

Close-up view of the binding interface between PCA062 (light cyan/violet ribbon), a therapeutic antibody drug conjugate and its target protein antigen, human P-cadherin (gold ribbon), a cell surface glycoprotein highly expressed in several human malignancies. Glutamate E155, a central epitope residue, is unique to human P-cadherin, thus conferring this antibody exquisite selectivity in delivering its toxic payload to P-cadherin expressing cancer cells. Read the full manuscript by Sheng and colleagues on page 1270.
Molecular Cancer Therapeutics

20 (7)

Mol Cancer Ther 2021;20:1221-1323.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/20/7

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/20/7.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.